Literature DB >> 17063322

Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Christopher Y Thomas1, Dan Theodorescu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17063322     DOI： 10.1007/s00345-006-0119-6

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  196 in total

1.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Authors:  Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

3.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.

Authors:  E M Messing
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

Review 5.  Targeting death receptors in bladder, prostate and renal cancer.

Authors:  Hugh F O'Kane; Chris J Watson; Samuel R Johnston; Istvan Petak; R William G Watson; Kate E Williamson
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

Review 6.  Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.

Authors:  Jingxuan Pan; Sai-Ching Jim Yeung
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Authors:  Wm Kevin Kelly; Victoria M Richon; Owen O'Connor; Tracy Curley; Barbara MacGregor-Curtelli; William Tong; Mark Klang; Lawrence Schwartz; Stacie Richardson; Eddie Rosa; Marija Drobnjak; Carlos Cordon-Cordo; Judy H Chiao; Richard Rifkind; Paul A Marks; Howard Scher
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

8.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

9.  Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.

Authors:  P Lipponen; M Eskelinen
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Authors:  A W Hitchings; M Kumar; S Jordan; V Nargund; J Martin; D M Berney
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640
View more
  5 in total

Review 1.  New and promising strategies in the management of bladder cancer.

Authors:  Andrea B Apolo; Nicholas J Vogelzang; Dan Theodorescu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

2.  Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen.

Authors:  Ling Chen; Wei Chen; Le Zhao; Hai-Zhen Yu; Xu Li
Journal:  World J Urol       Date:  2008-10-01       Impact factor: 4.226

3.  Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Authors:  Feng Lang; Ma Linlin; Tian Ye; Zhang Yuhai
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

4.  RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.

Authors:  Jianqi Yang; Lance T Platt; Biswanath Maity; Katelin E Ahlers; Zili Luo; Zhibo Lin; Bandana Chakravarti; Stella-Rita Ibeawuchi; Ryan W Askeland; Jolanta Bondaruk; Bogdan A Czerniak; Rory A Fisher
Journal:  Oncotarget       Date:  2016-10-25

5.  Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Authors:  Behfar Ehdaie; Dan Theodorescu
Journal:  Indian J Urol       Date:  2008-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.